Product Code: ETC8846630 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The NMOSD market in the Philippines is growing as awareness and diagnostic capabilities improve. Biologic therapies, immunosuppressants, and corticosteroids are commonly used to manage the condition. Increased research collaborations and expanded access to specialized neurology care are supporting market development.
The growing awareness of autoimmune neurological disorders and advancements in immunotherapy drive the NMOSD market in the Philippines. Increasing access to diagnostic tools and specialized treatment options enhances patient care. Additionally, rising investments in research and development for rare neurological conditions support market growth.
The NMOSD market in the Philippines faces challenges due to limited diagnostic capabilities and high treatment costs. NMOSD is a rare autoimmune disease that is often misdiagnosed due to a lack of awareness among healthcare providers. Advanced diagnostic tests required for accurate detection are expensive and not widely available. Additionally, long-term treatment with immunosuppressive drugs is costly, making it inaccessible to many patients.
NMOSD is a rare but severe autoimmune disorder affecting the central nervous system. The market for NMOSD treatments in the Philippines is growing due to increased awareness and improved diagnostic capabilities. Investors can target opportunities in biologic therapies, monoclonal antibodies, and immunosuppressive treatments. Collaborations with rare disease research institutions can help accelerate drug development and market entry.
NMOSD is classified as a rare disease under the Philippine Rare Disease Act, ensuring patients receive government support for diagnosis and treatment. Policies provide funding for specialized treatment centers and promote collaboration with international medical institutions for research on NMOSD therapies. The government also works to include NMOSD treatments in the national health insurance program to reduce the financial burden on patients.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market - Industry Life Cycle |
3.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market - Porter's Five Forces |
3.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By Dosage form, 2021 & 2031F |
3.8 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.10 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends |
6 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Types |
6.1 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies, 2021- 2031F |
6.1.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies, 2021- 2031F |
6.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Medication, 2021- 2031F |
6.2.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Immunosuppressive Agent, 2021- 2031F |
6.2.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By C5 Protein Inhibitor, 2021- 2031F |
6.2.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Monoclonal Antibodies, 2021- 2031F |
6.2.6 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Corticosteroids, 2021- 2031F |
6.2.7 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.2.8 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.2.9 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Dosage form |
6.3.1 Overview and Analysis |
6.3.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Tablets, 2021- 2031F |
6.3.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Injections, 2021- 2031F |
6.3.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.6.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Import-Export Trade Statistics |
7.1 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Export to Major Countries |
7.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Imports from Major Countries |
8 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Key Performance Indicators |
9 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market - Opportunity Assessment |
9.1 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By Dosage form, 2021 & 2031F |
9.4 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.6 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market - Competitive Landscape |
10.1 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenue Share, By Companies, 2024 |
10.2 Philippines Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |